Still Feeling Hungry on Wegovy — Is Something Wrong?

Week three, and you're still reaching for snacks at 10pm

You filled your first Wegovy prescription expecting the fridge to lose its appeal almost immediately. Instead, you're three weeks in, the dose is still 0.25mg, and the biscuit tin is just as persuasive as it ever was. That experience is clinically normal. The NHS patient information for semaglutide explains that the medicine works by mimicking a gut hormone called GLP-1, which influences appetite centres in the brain, but this effect is dose-dependent. The 0.25mg starting dose exists primarily to give your digestive system time to adjust, not to deliver the full therapeutic effect, and if you want a closer look at why you're still hungry on Wegovy at the 0.25mg stage, we cover that in detail separately. Appetite suppression tends to deepen meaningfully at the 1mg and 1.7mg stages, with many people reporting the clearest change around the 2.4mg maintenance dose.

So if you're still hungry on Wegovy in those first eight to twelve weeks, you are almost certainly on a dose that is not yet at its ceiling. Patience is unglamorous advice, but it is accurate. Sticking to the titration schedule matters, jumping a step because progress feels slow is not clinically safe, and missing doses disrupts the steady-state blood level the medicine relies on. If you're unsure about your schedule, the right person to ask is your prescriber, not a forum. It is also worth reading about what to expect if you're still hungry at the 0.5mg dose, since that step catches many people off guard too.

There is also a subtler point worth making: even at full dose, Wegovy is not designed to eliminate hunger entirely. The goal is a meaningful reduction that makes eating less feel manageable, not effortless. People who go into treatment expecting zero appetite sometimes experience a quite different but still effective result. If the broader question on your mind is why you are still hungry on Wegovy at all, our dedicated guide works through the most common reasons across the full titration journey.

The difference between hunger and appetite, it changes what you should do

Not all 'hunger' on Wegovy is the same thing. True physiological hunger, the physical discomfort that rises when your body genuinely needs fuel, and appetite-driven cravings, the mental pull towards food that is not tied to caloric need, respond differently to semaglutide. GLP-1 receptor agonists primarily dampen the reward-driven appetite signals; they are less powerful at eliminating the physical hunger that comes from undereating.

This distinction matters practically. If you are consuming too little protein or total calories while on Wegovy, your body will produce genuine hunger signals regardless of what the medicine is doing. What you eat on Wegovy shapes how well the medicine's appetite effect is felt: meals built around adequate protein (aiming for roughly 25–30g per meal is a reasonable starting point, though personal targets should come from your prescriber or a dietitian) and plenty of fibre slow gastric emptying further and extend satiety. Wegovy itself slows stomach emptying, so high-protein, high-fibre meals work alongside that mechanism rather than against it.

Sleep and stress are also genuinely relevant, not wellness clichés. Poor sleep raises ghrelin (a hunger-promoting hormone) and lowers leptin (the satiety signal), partially counteracting what semaglutide is trying to do. If your nights have been broken recently, that is a plausible contributor to feeling hungry on Wegovy despite being on a therapeutic dose. The NHS guidance on healthy weight and lifestyle covers the role of sleep and stress in weight management, it is worth reading alongside your treatment.

When persistent hunger is a signal to contact your prescriber

There is a point at which 'still hungry on Wegovy' moves from a normal early-treatment experience into something that deserves a clinical conversation. If you have been taking semaglutide at the 2.4mg maintenance dose for at least four weeks, you are eating in a reasonable calorie deficit, your protein and fibre intake is adequate, and hunger has not reduced at all, that pattern warrants discussion. It could reflect individual variation in how strongly you respond to GLP-1 receptor stimulation, in which case your prescriber may want to explore options including the newer 7.2mg maintenance dose, approved by the MHRA in January 2026 and now available as a single-dose weekly pen.

It is also worth checking in if hunger feels different from what you'd expect, very sudden, or accompanied by other symptoms. Nausea, stomach discomfort or changes in bowel habit are common at dose increases and are distinct from appetite; if anything worrying arises, contact your care team or seek medical advice promptly.

At nume, a real clinician reads your consultation before anything is prescribed or adjusted. If something is not working as expected, persistent hunger mid-treatment is exactly the kind of thing our prescribers can review. Our aftercare team is available seven days a week, if Monday's order arrives and you have questions by Wednesday, you are not waiting a week for answers.

For context on how Wegovy compares to tirzepatide in terms of appetite suppression and average weight outcomes, the Wegovy treatment overview lays out the published evidence. And if you are weighing up private treatment more broadly, our weight-loss treatment overview explains the options we prescribe and why clinical supervision shapes results as much as the medicine itself.

If you are considering starting Wegovy or want your current experience reviewed, start a free consultation with our prescribers, there is no obligation and no appointment to book.